Comparing PRESERFLO MicroShunt and trabeculectomy to lower eye pressure in open-angle glaucoma.
Official title: Preserflo MicroShunt Implantation Versus Trabeculectomy in Managing Open-Angle Glaucoma
Run by Medical University of Bialystok · NCT07496957 · Data updated 2026-11-12
This trial will test whether the PRESERFLO MicroShunt works as well as trabeculectomy to lower eye pressure in adults with open-angle glaucoma who need surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Medical University of Bialystok Academic / other |
| Locations | 1 site (Bialystok, Polska) |
| Status | Recruiting |
| Started | March 1, 2026 |
| Main results expected | December 1, 2027 |
| Study ends | December 1, 2028 |
| Registry record updated | March 27, 2026 |
| Trial ID | NCT07496957 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 21 with primary open-angle, normal-tension, pigment dispersion, or pseudoexfoliative glaucoma inadequately controlled on medications, with IOP 14–28 mmHg, MD ≤ -3, and endothelial cell count ≥1000 who are planning glaucoma surgery.
✕Probably not a fit
Patients with closed-angle glaucoma, secondary open-angle glaucomas other than pigment dispersion or pseudoexfoliation, prior conjunctival or glaucoma-shunt surgery, aphakia or anterior chamber IOL, intraocular silicone oil, no light perception, or current corticosteroid use are unlikely to be eligible or to benefit from this comparison.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with open-angle glaucoma who require surgical lowering of intraocular pressure are randomly assigned 1:1 to receive either the PRESERFLO MicroShunt implant or a trabeculectomy with mitomycin C during a single operation. Outcomes measured over 12 months include intraocular pressure reduction at 12 months, need for glaucoma medications, additional glaucoma procedures, complications, and visual and ocular-structure preservation. Participants attend scheduled follow-up visits for eye-pressure measurements, vision testing, and safety monitoring. The trial enrolls patients with primary open-angle, normal-tension, pigment dispersion, or pseudoexfoliative glaucoma who remain uncontrolled on maximal tolerated medical therapy.
Why it matters
Potential benefit: If successful, the MicroShunt could provide similar long-term eye-pressure control with a less invasive procedure and potentially fewer complications or faster recovery than trabeculectomy.
How similar studies have gone: Previous observational studies and some randomized trials suggest the PRESERFLO MicroShunt can lower IOP and reduce medication use, but long-term head-to-head data versus trabeculectomy remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: -\>21 years of age * An established diagnosis of: Primary open angle glaucoma, Normal tension glaucoma, Pigment dispersion glaucoma (PDG) or Pseudoexfoliative glaucoma (PEXG) * Inadequately controlled on maximum tolerated medical therapy * Mean Deviation (MD) \</= -3 * Intraocular pressure of 14-28 mmHg * Endothelial Cell Count ≥1000 cells/mm2 Exclusion Criteria: * An established diagnosis of: Closed-angle glaucoma or Secondary open-angle glaucoma (besides PDG and PEX) * Lens status: Aphakic patients or Anterior chamber intraocular lens * Previous procedures: Glaucoma shunt/valve/ surgery or cyclodestructive procedure, Selective laser trabeculoplasty within the past 3 months, Incisional ophthalmic surgery involving the conjunctiva within the past 3 months, Clear corneal cataract or trabecular meshwork surgery conducted within the past 6 months * Presence of intraocular silicone oil * No light perception vision * Current corticosteroid use (ocular or oral) * Conjunctival pathologies (e.g., pterygium) * Active inflammation (e.g., blepharitis, conjunctivitis, keratitis, uveitis) * Vitreous present in the anterior chamber * Active iris neovascularization or neovascularization of the iris within 6 months of the surgical date * Unwillingness or inability to give consent, accept randomization or return for and participate in scheduled protocol visits
Where it's running
-
Medical University of Bialystok
Bialystok, Polska, Poland Recruiting
Study contacts
- Study coordinator: Joanna Konopinska
- Email: joanna.konopinska@umb.edu.pl
- Phone: +48857468372
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Removing the ripcord from a glaucoma drainage device after 3 months
This study tests whether removing the ripcord from an implanted glaucoma drainage device changes eye pressure for adults with open-angle glaucoma.
-
Long-Term Results After Ab-interno Trabeculotomy for Glaucoma
This study tests whether ab-interno trabeculotomy with the Trabectome can provide sustained intraocular pressure reduction in glaucoma patients who had the procedure between 2019 and 2021.
-
XEN‑63 Gel Stent versus PRESERFLO MicroShunt for lowering eye pressure in open‑angle glaucoma.
This trial tests whether the PRESERFLO MicroShunt is at least as good as the XEN‑63 Gel Stent at lowering eye pressure over 12 months in adults with open‑angle glaucoma who need surgery.
-
G01 Eye Drops for Glaucomatous Optic Neuropathy
This trial tests whether G01 Eye Drops can help people with open-angle glaucoma who also have optic nerve injury.
-
Additive Physical Activity for Hypothyroidism in Older Women with Glaucoma and Fatty Liver
We’re testing whether adding a treadmill-based exercise program to standard thyroid treatment helps improve health in older women who have subclinical hypothyroidism, glaucoma, and fatty liver.
-
Lifestyle changes plus nightly CPAP for glaucoma in people with sleep apnea
This test checks whether adding a low-calorie diet and regular walking to nightly CPAP lowers eye pressure in people with high‑pressure open‑angle glaucoma who also have obstructive sleep apnea and obesity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.